Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Robert-Guroff Website

Marjorie Robert-Guroff, Ph.D.

Selected Publications
1)  Bogers W, Davis D, Baak I, Kan E, Hofman S, Sun Y, Mortier D, Lian Y, Oostermeijer H, Fagrouch Z, Dubbes R, van der Maas M, Mooij P, Koopman G, Verschoor E, Langedijk J, Zhao J, Brocca-Cofano E, Robert-Guroff M, Srivastava I, Barnett S, Heeney J.
Systemic HIV-1 neutralizing antibodies induced by replicating adenovirus-HIVenv prime/envelope protein or alphavirus replicon boost vaccination correlate with protection from mucosal SHIV challenge.
Virology. In Press, 2008. In Press. [Journal]
2)  Demberg T, Boyer JD, Malkevich N, Patterson LJ, Venzon D, Summers EL, Kalisz I, Kalyanaraman VS, Lee EM, Weiner DB, Robert-Guroff M.
Sequential priming with SIV DNA vaccines, with or without encoded cytokines, and a replicating Ad-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.
J. Virol. In Press, 2008. [Journal]
3)  Robert-Guroff M, Gallo R, inventor; DHHS, assignee.
A method for detecting HTLV-III neutralizing antibodies in sera.
US Patent: 4755457. 1988. [Patent]
4)  Robey F, Harris-Kelson T, Robert-Guroff M, inventor; DHHS, assignee.
Peptomers with enhanced immunogenicity.
US Patent: 5,750,332. 1998. [Patent]
5)  Broder S, Matsushita S, Robert-Guroff M, inventor; DHHS, assignee.
Therapeutic and diagnostic monoclonal antibody specific for human T-cell leukemia virus type I envelope protein.
US Patent: 4, 722,888. 1988. [Patent]
6)  Robert-Guroff M, Nabel GJ, Shiver JW. Levine MM, eds.
Replication-defective and competent adenovirus recombinants as vaccine vectors. In: New Generation Vaccines, 4th Edition. Volume .
New York: Informa Healthcare; 2008. In Press. [Book Chapter]
7)  Patterson LJ, Robert-Guroff M.
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.
Exp. Opin. Biol. Ther. 2008. In Press. [Journal]
8)  Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu S, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L.
The use of nonhuman primate models in HIV vaccine development.
PLos Med. 2008. In Press. [Journal]
9)  Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, Larsen K, Flanary L, Kalyanaraman VS, Pal R, Titti F, Patterson LJ, Heath MJ, O'Connor DH, Cafaro A, Ensoli B, Robert-Guroff M.
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.
Vaccine. 26: 3312-21, 2008. [Journal]
10)  Patterson LJ, Beal J, Demberg T, Florese RH, Malkevich N, Venzon D, Aldrich K, Richardson E, Kalyanaraman VS, Kalisz I, Lee EM, Montefiori DC, Robey FA, Robert-Guroff M.
Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
Virology. 374: 322-37, 2008. [Journal]
11)  Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, Patterson LJ, Korioth-Schmitz B, Buzby A, Dombagoda D, Montefiori DC, Letvin NL, Cafaro A, Ensoli B, Robert-Guroff M.
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
J. Virol. 81: 3414-27, 2007. [Journal]
12)  Zhou Q, Hidajat R, Peng B, Venzon D, Aldrich MK, Richardson E, Lee EM, Kalyanaraman VS, Grimes G, Gomez-Roman VR, Summers LE, Malkevich N, Robert-Guroff M.
Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).
Vaccine. 25: 8021-35, 2007. [Journal]
13)  Florese RH, Robert-Guroff M.
Non-neutralizing antibodies and vaccine-induced protection against HIV.
Future HIV Therapy. 1: 259-71, 2007. [Journal]
14)  Titti F, Cafaro A, Ferrantelli F, Tripiciano A, Moretti S, Caputo A, Gavioli R, Ensoli F, Robert-Guroff M, Barnett S, Ensoli B.
Problems and emerging approaches in HIV/AIDS vaccine development.
Expert opinion on emerging drugs. 12: 23-48, 2007. [Journal]
15)  Robert-Guroff M.
Replicating and non-replicating viral vectors for vaccine development.
Curr. Opin. Biotechnol. 18: 546-56, 2007. [Journal]
16)  Gomez-Roman VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M.
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.
J. Immunol. Methods. 308: 53-67, 2006. [Journal]
17)  Gomez-Roman VR, Florese RH, Peng B, Montefiori DC, Kalyanaraman VS, Venzon D, Srivastava I, Barnett SW, Robert-Guroff M.
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.
J. Acquir. Immune Defic. Syndr. 43: 270-7, 2006. [Journal]
18)  Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, Florese RH, Kalyanaraman VS, Pal R, Lee EM, Zhao J, Cristillo A, Robert-Guroff M.
Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIV(mac251) rectal challenge: Role of SIV-specific CD8+ T cell responses.
Virology. 353: 83-98, 2006. [Journal]
19)  Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M.
Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge.
J. Immunol. 177: 4028-36, 2006. [Journal]
20)  Gomez-Roman VR, Grimes GJ, Potti GK, Peng B, Demberg T, Gravlin L, Treece J, Pal R, Lee EM, Alvord WG, Markham PD, Robert-Guroff M.
Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.
Vaccine. 24: 5064-72, 2006. [Journal]
21)  Peng B, Voltan R, Cristillo AD, Alvord WG, Davis-Warren A, Zhou Q, Murthy KK, Robert-Guroff M.
Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity.
AIDS. 20: 2149-57, 2006. [Journal]
22)  Rosati M, von Gegerfelt A, Roth P, Alicea C, Valentin A, Robert-Guroff M, Venzon D, Montefiori DC, Markham P, Felber BK, Pavlakis GN.
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.
J Virol. 79: 8480-92, 2005. [Journal]
23)  Zhao J, Voltan R, Peng B, Davis-Warren A, Kalyanaraman VS, Alvord WG, Aldrich K, Bernasconi D, Buttò S, Cafaro A, Ensoli B, Robert-Guroff M.
Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Virology. 342: 1-12, 2005. [Journal]
24)  Pinczewski J, Zhao J, Malkevitch N, Patterson LJ, Aldrich K, Alvord WG, Robert-Guroff M.
Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE.
Viral Immunol. 18: 236-43, 2005. [Journal]
25)  Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M.
Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.
J Virol. 79: 10200-10209, 2005. [Journal]
26)  Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G.
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.
J Infect Dis. 191: 372-81, 2005. [Journal]
27)  Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M.
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.
J Immunol. 174: 2185-9, 2005. [Journal]
28)  Malkevitch NV, Robert-Guroff M.
A call for replicating vector prime-protein boost strategies in HIV vaccine design.
Expert Rev Vaccines. 3 Suppl 1: S105-17, 2004. [Journal]
29)  Malkevitch N, Rohne D, Pinczewski J, Aldrich K, Kalyanaraman VS, Letvin NL, Robert-Guroff M.
Evaluation of combination DNA/replication competent Ad-SIV recombinant immunization regimens in rhesus macaques.
AIDS Res. Human Retroviruses. 20: 235-244, 2004. [Journal]
30)  Patterson L, Peng B, Nan X, Robert-Guroff M.
Live adenovirus recombinants as vaccine vectors.
In: Levine MM, Kaper JB, Rappuoli R, Liu M, Good MF, Eds. New Generation Vaccines, 3rd Edition: New York, Marcel Dekker, Inc.; 325-335, 2004. [Journal]
31)  Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M.
Protection against mucosal SIVmac251 challenge using replicating adenovirus-SIV multi-gene vaccine priming and subunit boosting.
J Virol. 78: 2212-2221, 2004. [Journal]
32)  Malkevitch N, Patterson LJ, Aldrich K, Richardson E, Alvord WG, Robert-Guroff M.
A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in mamu-A*01 rhesus macaques.
J Immunol. 170: 4281-9, 2003. [Journal]
33)  Gomez-Roman VR, Robert-Guroff M.
Adenoviruses as vectors for HIV vaccines.
AIDS Reviews. 5: 178-185, 2003. [Journal]
34)  Zhao J, Lou Y, Pinczewski J, Malkevitch N, Aldrich K, Kalyanaraman VS, Venzon D, Peng B, Patterson LJ, Edghill-Smith Y, Woodward R, Pavlakis GN, Robert-Guroff M.
Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants.
Vaccine. 21: 4022-35, 2003. [Journal]
35)  Nan X, Peng B, Hahn TW, Richardson E, Lizonova A, Kovesdi I, Robert-Guroff M.
Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.
Gene Ther. 10: 326-36, 2003. [Journal]
36)  Zhao J, Pinczewski J, Gómez-Román VR, Venzon D, Kalyanaraman VS, Markham PD, Aldrich K, Moake M, Montefiori DC, Lou Y, Pavlakis GN, Robert-Guroff M.
Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
J Virol. 77: 8354-65, 2003. [Journal]
37)  Voltan R, Robert-Guroff M.
Live recombinant vectors for AIDS vaccine development.
Curr Mol Med. 3: 273-84, 2003. [Journal]
38)  Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K, Kalyanaraman VS, Pavlakis GN, Robert-Guroff M.
Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.
J Virol. 77: 8607-20, 2003. [Journal]
39)  Edghill-Smith YY, Aldrich K, Zhao J, Pinczewski J, Kalyanaraman VS, Johnson M, Heyliger A, Perrin RP, Woodward R, Robert-Guroff M.
Effects of intestinal survival surgery on systemic and mucosal immune responses in SIV-infected rhesus macaques.
J Med Primatol. 31: 313-22, 2002. [Journal]
40)  Robert-Guroff M.
HIV regulatory and accessory proteins: new targets for vaccine development.
DNA Cell Biol. 21: 597-8, 2002. [Journal]
41)  Patterson LJ, Prince GA, Richardson E, Alvord WG, Kalyan N, Robert-Guroff M.
Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion.
Virology. 292: 107-13, 2002. [Journal]
42)  Patterson LJ, Malkevitch N, Zhao J, Peng B, Robert-Guroff M.
Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.
DNA Cell Biol. 21: 627-35, 2002. [Journal]
43)  Peng B, Voltan R, Lim L, Edghill-Smith Y, Phogat S, Dimitrov DS, Arora K, Leno M, Than S, Woodward R, Markham PD, Cranage M, Robert-Guroff M.
Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.
J Virol. 76: 6016-26, 2002. [Journal]
44)  Patterson LJ, Robey F, Muck A, Van Remoortere K, Aldrich K, Richardson E, Alvord WG, Markham PD, Cranage M, Robert-Guroff M.
A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge.
AIDS Res Hum Retroviruses. 17: 837-49, 2001. [Journal]
45)  Robey FA, Robert-Guroff M.
A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells.
AIDS Res Hum Retroviruses. 17: 533-41, 2001. [Journal]
46)  Peng B, Robert-Guroff M.
Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation.
Immunol Lett. 78: 195-200, 2001. [Journal]
47)  Robert-Guroff M, Buehring G. Goedert J, eds.
In pursuit of a human breast cancer virus: from mouse to human. In: Infectious Causes of Cancer: Targets for Intervention. Volume .
Totowa: Humana Press Inc.; 2000. p. 475-487 [Book Chapter]
48)  Leno M, Kowalski M, Robert-Guroff M.
CD8 T cell anti-HIV activity as a complementary protective mechanism in vaccinated chimpanzees.
AIDS. 14: 893-4, 2000. [Journal]
49)  Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M.
Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
AIDS. 14: 2445-55, 2000. [Journal]
50)  Robert-Guroff M.
IgG surfaces as an important component in mucosal protection.
Nat Med. 6: 129-30, 2000. [Journal]
51)  Margolis L, Glushakova S, Chougnet C, Shearer G, Markham P, Robert-Guroff M, Benveniste R, Miller CJ, Cranage M, Hirsch V, Franchini G.
Replication of simian immunodeficiency virus (SIV) in ex vivo lymph nodes as a means to assess susceptibility of macaques in vivo.
Virology. 275: 391-7, 2000. [Journal]
52)  Lian Y, Barnett S, Gomez-Roman V, Peng B, Robert-Guroff M, Srivastava I, inventor; DHHS, assignee.
Combination Approaches For Generating Immune Responses.
Patent Pending, Filed in 2005. Application No. 10/571,882. Pending [Patent]
53)  Barnett S, Gomez-Roman V, Robert-Guroff M, Srivastava I, inventor; DHHS, assignee.
Combination Approaches For Generating Immune Responses.
Patent Pending, Filed in 2006. Application No. 11/664,962. Pending [Patent]
54)  Robert-Guroff M, Ensoli B, Peng B, Voltan R, inventor; DHHS, assignee.
Improved Replication-competent Adenovirus Vectors.
Patent Pending, Filed in 2004. Application No. 11/282,319. Pending [Patent]

This page was last updated on 9/25/2008.